Oncogenic Kras Requires Simultaneous PI3K Signaling to Induce ERK Activation and Transform Thyroid Epithelial Cells In vivo

Kelly A. Miller,1 Nicole Yeager,1 Kristen Baker,4 Xiao-Hui Liao,2 Samuel Refetoff,1,3 and Antonio Di Cristofano1

1Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Departments of Medicine and Pediatrics and Committee on Genetics, University of Chicago, Chicago, Illinois; and 2Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York

Abstract

Thyroid tumors arising from the follicular cells often harbor mutations leading to the constitutive activation of the PI3K and Ras signaling cascades. However, it is still unclear what their respective contribution to the neoplastic process is, as well as to what extent they interact. We have used mice harboring a Kras oncogenic mutation and a Pten deletion targeted to the thyroid epithelium to address in vivo these questions. Here, we show that although each of these two pathways, alone, is unable to transform thyroid follicular cells, their simultaneous activation is highly oncogenic, leading to invasive and metastatic follicular carcinomas. In particular, phosphatidylinositol-3-kinase (PI3K) activation suppressed Kras-initiated feedback signals that uncouple mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) and ERK activation, thus stunting MAPK activity; in addition, PI3K and Kras cooperated to drastically up-regulate cyclin D1 mRNA levels. Finally, combined pharmacologic inhibition of PI3K and MAPK completely inhibited the growth of double-mutant cancer cell lines, providing a compelling rationale for the dual targeting of these pathways in thyroid cancer. [Cancer Res 2009;69(8):3689–94]

Introduction

Activating mutations of Ras family members are common in thyroid cancer originating from the follicular epithelium (1). Several transgenic approaches have been used in the past to define the molecular mechanisms of Ras-mediated thyroid transformation (2, 3). However, it is now clear that supraphysiologic expression often results in phenotypes that do not really model the activity of oncogenic Ras expressed at endogenous levels (4). The development of mouse strains that more faithfully reproduce the expression of mutant Ras seen in human cancers has recently allowed a more accurate analysis of the mechanisms involved in tumor development and progression, and of Ras cross-talk with cooperating oncogenic alterations (5, 6).

Aberrant activation of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway plays an extensive role in thyroid tumorigenesis, particularly in follicular (55%) and anaplastic thyroid cancer (58%), and promotes progression of benign adenomas to follicular thyroid cancer and to anaplastic thyroid cancer as the genetic alterations of this pathway accumulate (7, 8). Furthermore, the frequencies and overlap of genetic alterations in the PI3K and Ras/mitogen-activated protein kinase (MAPK) cascades increase with progression from differentiated to undifferentiated thyroid tumors: alterations in PI3K and MAPK pathways occur in nearly all high-grade tumors, with the majority of the cases harboring genetic alterations in both pathways (8). To understand how PI3K activation cooperates with activation of Ras in promoting thyroid cancer pathogenesis, we have used an in vivo approach in genetically defined mouse models.

Materials and Methods

Animals and treatments. The KrasLSL, Pten+/−, and thyroid peroxidase promoter (TPO)-Cre strains have been described (9–11). All strains were backcrossed in the 129Sv background for at least eight generations. Iy290402 (Cayman Chemical) was injected i.p. at 25 mg/kg body weight twice a week, starting at age 3 wk.

Hormone measurements. Blood was collected by cardiac puncture. Serum thyroid-stimulating hormone (TSH) was measured using a sensitive, heterologous, disequilibrium double-antibody precipitation RIA (12), and results were expressed in mU/liter. All samples were individually analyzed for each mouse. Total T4 concentrations were measured by a solid-phase RIA (Coat-a-Count; Diagnostic Products Corp.) adapted for mice. Values of the respective limits of assay sensitivities were assigned to samples with undetectable TSH and T4 concentration.

Immunohistochemistry. Six-micrometer sections were subjected to antigen retrieval, incubated with pERK1/2 (Thr202/Tyr204) and pAKT (Ser473) antibodies (Cell Signaling), and counterstained with hematoxylin. SA-β-galactosidase activity was detected using a commercially available kit (Cell Signaling).

Cells, treatments, and proliferation analysis. Several independent cell lines were established from primary thyroid tumors developed by Pten+/−, KrasG12D double-mutant (DM) mice5 and grown in DMEM/10% fetal bovine serum. Pharmacologic inhibitors of PI3K (LY294002, 30 μmol/l) and MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK) 1 (PD98059, 50 μmol/l) were added 24 h after plating, in quadruplicate. At the indicated time points, cells were counted using a Beckman Coulter counter or harvested in RIPA buffer for protein analysis and in Trizol (Invitrogen) for RNA analysis.

Western blot analysis. Thyroids and cells were homogenized on ice in RIPA buffer supplemented with Complete protease inhibitor tablet (Roche). Western blot analysis was carried out on 20 to 40 μg proteins with the following antibodies: MEK, pMEK (Ser217/221), ERK1/2, pERK1/2 (Thr202/Tyr204) (Cell Signaling), and cyclin D1 (Becton Dickinson).

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

References for reprints: Antonio Di Cristofano, Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Price Center for Genetic and Translational Medicine, 1301 Morris Park Avenue, Room 302, Bronx, NY 10461. Phone: 718-678-1137; Fax: 718-678-1020; E-mail: adicrist@aecom.yu.edu.

©2009 American Association for Cancer Research. doi:10.1158/0008-5472.CAN-09-0024
Real-time PCR. Total RNA was extracted with Trizol and reverse transcribed using the Thermoscript kit (Invitrogen). qRT-PCR was performed on an ABI-7900 using TaqMan Master mix and primers (Applied Biosystems). Each sample was run in triplicate and β-actin was used to control for input RNA. Data analysis was based on the Ct method, and experiments were repeated at least thrice using at least two independent pools. The RT² Profiler Mouse MAPK PCR Array (SA Biosciences), containing 84 genes related to the MAPK pathway, plus housekeeping genes and controls, was used to analyze MAPK-related gene expression in the thyroids. Total RNA from pools of three to five mice was extracted with Trizol and further purified using the RNeasy Mini kit (Quiagen). RNA was reverse-transcribed with the First Strand kit (SA Biosciences), combined with the SYBR Green/ROX PCR master mix (SA Biosciences), and added to each well of the RT² Profiler PCR plate, containing the predispensed gene-specific primer sets. The reaction was run on an ABI-7900. Data analysis was based on the Ct method, with normalization to four different housekeeping genes, on quadruplicate samples from two independent thyroid pools.

Statistical analysis. Experiments were performed at least thrice. Data were analyzed using the JMP 5.1 software package. Differences with P values of 0.05 were considered statistically significant.

Results

To investigate the role of Ras in the pathogenesis of thyroid cancer, we have generated a mouse strain in which an oncogenic Kras mutant allele, G12D, is conditionally expressed in the thyroid epithelium through Cre-mediated deletion of a floxed STOP cassette preventing KrasG12D expression. This allele is targeted to its endogenous genomic locus, thus yielding physiologic expression levels of the mutant transcript (9). Tissue specificity is dictated by the human TPO, driving Cre expression in the follicular cells starting at day 14.5 of embryonic development (10).

TPO-Cre efficiently excised the STOP cassette (Supplementary Fig. S1A), leading to the expression of the oncogenic allele at endogenous levels. Kras mutant mice were born at the expected Mendelian frequencies and, throughout their lives, were indistinguishable from their wild-type littermates. Surprisingly, constitutive activation of Kras did not lead to morphologic (Fig. 1A) or functional (Fig. 2A) alterations of the thyroid gland, at least up to age 1 year. This result is in striking contrast with the ability of the
same allele to induce pancreatic intraepithelial neoplasia by age 2 weeks (13), colonic hyperplasia 2 weeks after activation (14), and lung hyperplasia 2 weeks after activation (9).

Ras activation, in certain cell types, leads to a negative feedback that down-regulates MAPK signaling and may induce senescence (15–17). On the other hand, genetic (7, 8) and epigenetic (18) alterations causing the activation of the PI3K pathway have recently been identified in most thyroid cancers. Thus, in thyroid follicular cells, Kras activating mutations might need the simultaneous activation of PI3K signaling to fully realize their oncogenic potential.

To test this hypothesis, we crossed the KrasG12D;TPO-Cre mice with Pten+/–;TPO-Cre mice, which have hyperplastic thyroids as a result of constitutively active PI3K signaling (Supplementary Fig. S1B; Fig. 1A), and progress to develop adenomas by age 10 months (19, 20). Strikingly, all the double-mutant (DM) mice rapidly developed thyroid follicular carcinomas (Fig. 1A). Fifty percent of the mice died within 7 weeks from birth, and none survived over age 4 months (Fig. 1B). These mice developed thyroids 200- to 500-fold larger than control glands (data not shown). PCR analysis showed that both the Pten and the Kras locus had undergone appropriate Cre-mediated recombination (Fig. 1C). Accordingly, follicular cells in both Pten–/– and KrasG12D glands showed dramatically increased pAKT levels (Supplementary Fig. S1B). Histopathology of the DM mice revealed that 30% to 90% of the thyroid glands was replaced by microfollicular to solid areas (Supplementary Fig. S2) presenting many hallmarks of thyroid follicular cancer, including capsular, muscle, and vascular invasion. In addition, all the mice surviving at least 12 weeks developed thyroglobulin-positive lung metastases (Supplementary Fig. S3; Fig. 1D).

To assess the thyroid functional status in the four strains, and to determine whether the tumors depend on TSH signaling, we measured TSH and T4 in the serum of control and mutants. Although single gene mutation did not alter the levels of either hormone, TSH was drastically reduced and T4 increased in the DM mice, suggesting that simultaneous PI3K and Kras activation may confer a certain degree of thyroid autonomy (Fig. 2A). Although we still do not know the basis for this TSH-independent thyroid hormone synthesis, TSH suppression strongly suggests that tumor development, in this model, does not rely on TSH-mediated proliferative signals.

In several mouse models, endogenous Kras activation seems to be unable to fully activate MAPK signaling (4, 14). We analyzed the phosphorylation of MEK and its direct target ERK in the thyroids of the four strains. PI3K activation in Pten–/– thyroid glands reduced ERK phosphorylation to the same extent as derived cells reduced ERK phosphorylation to the same extent as
direct MEK inhibition (Fig. 3B), and led to the establishment of senescence (Fig. 3C), strongly suggesting that activation of Kras alone is not transforming because of a PI3K-sensitive negative feedback that uncouples MEK and ERK, terminates the MAPK cascade, and establishes senescence.

To test in vivo the permissive role of PI3K in Kras-dependent transformation, we administered LY294002 twice a week to DM mice at a low dose of 25 mg/kg (21), starting at age 3 weeks. PI3K inhibition significantly prolonged the survival of LY-treated mice, compared with untreated mice (Fig. 3D). These data are consistent with the results obtained on the tumor-derived cell lines, and support the notion that continuous PI3K signaling is necessary to permit the transforming activity of oncogenic Kras mutations.

We then used a qRT-PCR array to measure the expression of 84 genes associated with MAPK signaling in thyroid RNA from the 4 strains, trying to identify relevant targets of the cooperation between PI3K and Kras. Analysis of the expression of these genes identified a subgroup of transcripts specifically up-regulated in the DM mice, compared with wild-type thyroids (Fig. 4A). We have initially focused on these genes as prime candidates to mediate the combined transforming activity of PI3K and Kras, and in particular on cyclin D1.

Cyclin D1 transcript levels were up-regulated over 4-fold in the compound mutants, compared with both wild-type and single-mutant mice (Fig. 4B). In contrast, the expression levels of the other D-type cyclins, D2 and D3, were not significantly altered in any of the mutant strains. Accordingly, when we inhibited PI3K and/or MAPK signaling in tumor-derived cell lines, cyclin D1 transcript levels (but not D2 or D3) were down-regulated (again, ~ 4-fold) by simultaneous LY294002 and PD98059 treatment (Fig. 4C), thus validating our data obtained in vivo. Finally, we used Western blot analysis to prove that cyclin D1 protein expression followed the same pattern observed at the mRNA level. DM thyroids expressed much higher cyclin D1 protein than any of the single-mutant strains, and simultaneous PI3K and MAPK inhibition dramatically reduced cyclin D1 protein levels in tumor-derived cell lines (Fig. 4D).
Discussion

Expression of oncogenic Kras at physiologic levels using the KrasLSL mouse model (9) invariably results in the development of hyperplastic lesions that often progress and transform into carcinomas. For example, Kras activation in the lungs through intranasal instillation of Cre-expressing adenoviral vectors results in the development of hyperplasia as early as 4 days after activation (4) and adenocarcinomas by age 16 weeks (9). Similarly, expression of endogenous KrasG12D in the exocrine pancreas induces intraepithelial neoplasms by age 2 weeks and carcinomas after 6 months (13). It was thus surprising to find that oncogenic Kras activation in the thyroid follicular cells did not lead to any morphologic and functional alterations of the thyroid gland. Although it is possible that the strain in which these experiments have been performed (129Sv) harbors genetic modifiers of Kras activity not present in the strain used in the previous reports, it is more likely that the thyroid has specific mechanisms in place to limit the effect of oncogenic Kras mutations, and leading to a senescence-like state through the up-regulation of known negative regulators of oncogenic Ras including Sprouty-2 (17), dual-specificity phosphatases (22), and Ras-GAPs (15).
The finding that PI3K activation through loss of Pten is able to unleash the full oncogenic potential of the Kras allele strongly suggests that PI3K may oppose such negative feedbacks, possibly through direct regulation of the expression level or enzymatic activity of these molecules.

As a result, we show that simultaneous activation of PI3K and Kras leads to the up-regulation of a group of genes that likely play an active role in the transformation process, similar to what has been recently described by Iwanaga and colleagues (23) in an analogous model of accelerated lung tumorigenesis. Although it is not surprising to find, among these culprits, Cyclin D1, a shared target of both Kras (24) and PI3K (25), from a biological standpoint, it is more puzzling the presence of Cdkn2a. Although it is possible that p14/p16 up-regulation represents an attempt of thyrocyte to counter the hyperproliferative signals generated by Kras and PI3K, additional studies are warranted to fully understand this finding. Nonetheless, it is worthy of note that Cdkn2a up-regulation has been frequently reported in thyroid carcinomas (26–28).

In conclusion, using the mouse thyroid as a model system, our studies have uncovered a tight dependence of PI3K transforming ability, in vitro, on constitutive PI3K signaling, which is required to allow full MAPK activation and cyclin D1 overexpression. Ongoing studies will address both the mechanistic details of this cooperative signaling, and the identity of additional clinically and therapeutically relevant targets.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 1/6/09; revised 1/29/09; accepted 2/16/09; published OnlineFirst 4/7/09.

Grant support: Fox Chase Cancer Center Core grant by the NCI Core grant and by NIH grants (CA97097 and CA128943; A. Di Cristofano) and (DK15070 and DK20595; S. Refetoff).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Tyler Jacks for the Kras<sup>12D</sup> mice; the Transgenic, Laboratory Animal, Biomarker, and Histopathology facilities of Fox Chase Cancer Center, and the Animal Facility of Einstein.

References


Oncogenic Kras Requires Simultaneous PI3K Signaling to Induce ERK Activation and Transform Thyroid Epithelial Cells In vivo

Kelly A. Miller, Nicole Yeager, Kristen Baker, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-09-0024

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2009/04/28/0008-5472.CAN-09-0024.DC1

Cited articles
This article cites 28 articles, 10 of which you can access for free at:
http://cancerres.aacrjournals.org/content/69/8/3689.full#ref-list-1

Citing articles
This article has been cited by 15 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/69/8/3689.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.